Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel

Intern Med. 2021 Oct 15;60(20):3273-3277. doi: 10.2169/internalmedicine.6442-20. Epub 2021 Apr 12.

Abstract

Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular carcinoma (HCC). A 72-year-old man was admitted for the evaluation of an abnormal shadow on his lung. Computed tomography revealed a lung nodule in the right upper lobe and multiple liver masses. He was diagnosed with synchronous primary lung adenocarcinoma and HCC. Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) chemotherapy was efficacious for both tumors. ABCP chemotherapy may be a potential treatment option for synchronous primary lung adenocarcinoma and HCC.

Keywords: atezolizumab; bevacizumab; hepatocellular carcinoma; lung cancer; multiple primary malignancies.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung* / diagnostic imaging
  • Adenocarcinoma of Lung* / drug therapy
  • Aged
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / therapeutic use
  • Carboplatin / therapeutic use
  • Carcinoma, Hepatocellular* / diagnostic imaging
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / drug therapy
  • Lung
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / drug therapy
  • Male
  • Neoplasms, Multiple Primary* / diagnostic imaging
  • Neoplasms, Multiple Primary* / drug therapy
  • Paclitaxel / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • atezolizumab
  • Carboplatin
  • Paclitaxel